Download PDF
Semin Neurol 2004; 24(4): 419-426
DOI: 10.1055/s-2004-861536
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Neurotoxicity of Cancer Chemotherapy

Edward J. Dropcho1
  • 1Professor of Neurology, Department of Neurology, Indiana University Medical Center, and The Indianapolis Veterans Affairs Medical Center, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
07 January 2005 (online)

    Permissions and Reprints

ABSTRACT

Neurological dysfunction is a common side effect of many chemotherapy drugs. For several agents neurotoxicity is common, severe, and can be dose-limiting. This is a review of the clinical features of chemotherapy-induced syndromes involving the central and peripheral nervous systems.

KEYWORDS

Chemotherapy adverse effects - polyneuropathy

REFERENCES

  • 1 Vassal G, Deroussent A, Hartmann O et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.  Cancer Res. 1990;  50 6203-6207
    PubMedGoogle Scholar
  • 2 Wyllie A R, Bayliff C D, Kovacs M J. Myoclonus due to chlorambucil in two adults with lymphoma.  Ann Pharmacother. 1997;  31 171-174
    PubMedGoogle Scholar
  • 3 Dropcho E J, Rosenfeld S S, Vitek J, Guthrie B L, Morawetz R B. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.  J Neurooncol. 1998;  36 191-198
    CrossrefPubMedGoogle Scholar
  • 4 Baker W J, Royer G L, Weiss R B. Cytarabine and neurologic toxicity.  J Clin Oncol. 1991;  9 679-693
    PubMedGoogle Scholar
  • 5 Jaeckle K A, Batchelor T, O'Day S J et al.. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.  J Neurooncol. 2002;  57 231-239
    CrossrefPubMedGoogle Scholar
  • 6 Leff R S, Thompson J M, Daly M B et al.. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.  Cancer. 1988;  62 32-35
    CrossrefPubMedGoogle Scholar
  • 7 Pratt C B, Green A A, Horowitz M E et al.. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.  J Clin Oncol. 1986;  4 1253-1261
    PubMedGoogle Scholar
  • 8 Pratt C B, Goren M P, Meyer W H, Singh B, Dodge R K. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.  J Clin Oncol. 1990;  8 1399-1401
    PubMedGoogle Scholar
  • 9 DiMaggio J R, Brown R, Baile W F, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity.  Cancer. 1994;  73 1509-1514
    CrossrefPubMedGoogle Scholar
  • 10 Simonian N A, Gilliam F G, Chiappa K H. Ifosfamide causes a diazepam-sensitive encephalopathy.  Neurology. 1993;  43 2700-2702
    PubMedGoogle Scholar
  • 11 Pelgrims J, De Vos F, Van den Brande J et al.. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.  Br J Cancer. 2000;  82 291-294
    CrossrefPubMedGoogle Scholar
  • 12 Pavol M A, Meyers C A, Rexer J L et al.. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.  Neurology. 1995;  45 947-950
    PubMedGoogle Scholar
  • 13 Valentine A D, Meyers C A, Kling M A, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy.  Semin Oncol. 1998;  25(Suppl 1) 39-47
    PubMedGoogle Scholar
  • 14 Hensley M L, Peterson B, Silver R T et al.. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia.  J Clin Oncol. 2000;  18 1301-1308
    PubMedGoogle Scholar
  • 15 Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.  J Neurooncol. 1988;  6 355-359
    PubMedGoogle Scholar
  • 16 Meyers C A, Scheibel R S, Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha.  Neurology. 1991;  41 672-676
    PubMedGoogle Scholar
  • 17 Musselman D L, Lawson D H, Gumnick J F et al.. Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 961-966
    CrossrefPubMedGoogle Scholar
  • 18 Denicoff K D, Rubinow D R, Papa M Z et al.. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.  Ann Intern Med. 1987;  107 293-300
    PubMedGoogle Scholar
  • 19 Karp B I, Yang J C, Khorsand M, Wood R, Merigan T C. Multiple cerebral lesions complicating therapy with interleukin-2.  Neurology. 1996;  47 417-424
    PubMedGoogle Scholar
  • 20 Baz D V, Bofill J S, Noguiera J A. Irinotecan-induced dysarthria.  J Natl Cancer Inst. 2001;  93 1419-1420
    CrossrefPubMedGoogle Scholar
  • 21 Sullivan K M, Storb R, Shulman H M et al.. Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation.  Ann Intern Med. 1982;  97 182-189
    PubMedGoogle Scholar
  • 22 Nieto Y, Cagnoni P J, Bearman S I et al.. Acute encephalopathy: a new toxicity associated with high-dose Paclitaxel.  Clin Cancer Res. 1999;  5 501-506
    PubMedGoogle Scholar
  • 23 Perry J R, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion.  Neurology. 1996;  46 1596-1599
    PubMedGoogle Scholar
  • 24 Byrd R L, Rohrbaugh T M, Raney R B, Norris D G. Transient cortical blindness secondary to vincristine therapy in childhood malignancies.  Cancer. 1981;  47 37-40
    CrossrefPubMedGoogle Scholar
  • 25 Hurwitz R L, Mahoney D H, Armstrong D L, Browder T M. Reversible encephalopathy and seizures as a result of conventional vincristine administration.  Med Pediatr Oncol. 1988;  16 216-219
    CrossrefPubMedGoogle Scholar
  • 26 Rosenblum M K, Delattre J Y, Walker R W, Shapiro W R. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.  J Neurooncol. 1989;  7 269-281
    PubMedGoogle Scholar
  • 27 Hook C C, Kimmel D W, Kvols L K et al.. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.  Ann Neurol. 1992;  31 262-267
    CrossrefPubMedGoogle Scholar
  • 28 Savarese D M, Gordon J, Smith T W et al.. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole.  Cancer. 1996;  77 387-394
    CrossrefPubMedGoogle Scholar
  • 29 Franco D A, Greenberg H S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.  Neurology. 2001;  56 110-112
    CrossrefPubMedGoogle Scholar
  • 30 Takimoto C H, Lu Z H, Zhang R et al.. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.  Clin Cancer Res. 1996;  2 477-481
    PubMedGoogle Scholar
  • 31 Herrlinger U, Schabet M, Brugger W et al.. Primary central nervous system lymphoma: outcome and late adverse effects after combined modality treatment.  Cancer. 2001;  91 130-135
    CrossrefPubMedGoogle Scholar
  • 32 Robain O, Dulac O, Dommergues J P et al.. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia.  J Neurol Neurosurg Psychiatry. 1984;  47 65-72
    CrossrefPubMedGoogle Scholar
  • 33 Miyatake S, Kikuchi H, Oda Y et al.. A case of treatment-related leukoencephalopathy: sequential MRI, CT and PET findings.  J Neurooncol. 1992;  14 143-149
    PubMedGoogle Scholar
  • 34 Rubinstein L J, Herman M M, Long T F, Wilbur J R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma.  Cancer. 1975;  35 291-305
    CrossrefPubMedGoogle Scholar
  • 35 Chun H G, Leyland-Jones B R, Caryk S M, Hoth D F. Central nervous system toxicity of fludarabine phosphate.  Cancer Treat Rep. 1986;  70 1225-1228
    PubMedGoogle Scholar
  • 36 Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs.  J Clin Oncol. 1994;  12 2216-2228
    PubMedGoogle Scholar
  • 37 Cohen R B, Abdallah J M, Gray J R, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.  Ann Intern Med. 1993;  118 114-116
    CrossrefPubMedGoogle Scholar
  • 38 Feinberg W M, Swenson M R. Cerebrovascular complications of L-asparaginase therapy.  Neurology. 1988;  38 127-133
    CrossrefPubMedGoogle Scholar
  • 39 Mitchell L G. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase.  Cancer. 2003;  97 508-515
    CrossrefPubMedGoogle Scholar
  • 40 Icli F, Karaoguz H, Dincol D et al.. Severe vascular toxicity associated with cisplatin-based chemotherapy.  Cancer. 1993;  72 587-593
    Google Scholar
  • 41 El Amrani M, Henizlef O, Debroucker T et al.. Brain infarction following 5-fluorouracil and cisplatin therapy.  Neurology. 1998;  51 899-901
    PubMedGoogle Scholar
  • 42 Bernard J T, Ameriso S, Kempf R A et al.. Transient focal neurologic deficits complicating interleukin-2 therapy.  Neurology. 1990;  40 154-155
    PubMedGoogle Scholar
  • 43 Walker R W, Allen J C, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate.  J Clin Oncol. 1986;  4 1845-1850
    PubMedGoogle Scholar
  • 44 Rubnitz J E, Relling M V, Harrison P L et al.. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.  Leukemia. 1998;  12 1176-1181
    CrossrefPubMedGoogle Scholar
  • 45 Ay H, Buonanno F S, Schaefer P W et al.. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI.  Neurology. 1998;  51 1369-1376
    CrossrefPubMedGoogle Scholar
  • 46 Shin R K, Stern J W, Janss A J, Hunter J V, Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia.  Neurology. 2001;  56 388-391
    CrossrefPubMedGoogle Scholar
  • 47 Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children.  Pediatr Neurol. 2001;  24 145-148
    CrossrefPubMedGoogle Scholar
  • 48 Henderson R D, Rajah T, Nicol A J, Read S J. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.  Neurology. 2003;  60 326-328
    PubMedGoogle Scholar
  • 49 Smith G A, Damon L E, Rugo H S, Ries C A, Linker C A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.  J Clin Oncol. 1997;  15 833-839
    PubMedGoogle Scholar
  • 50 Winkelman M D, Hines J D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study.  Ann Neurol. 1983;  14 520-527
    CrossrefPubMedGoogle Scholar
  • 51 Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series.  J Neurooncol. 1997;  34 163-167
    CrossrefPubMedGoogle Scholar
  • 52 Anderson N R, Tandon D S. Ifosfamide extrapyramidal neurotoxicity.  Cancer. 1991;  68 72-75
    CrossrefPubMedGoogle Scholar
  • 53 Resar L M, Phillips P C, Kastan M B et al.. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type.  Cancer. 1993;  71 117-123
    CrossrefPubMedGoogle Scholar
  • 54 Raney B, Tefft M, Heyn R et al.. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma.  Cancer. 1992;  69 1498-1506
    CrossrefPubMedGoogle Scholar
  • 55 McLean D R, Clink H M, Ernst P et al.. Myelopathy after intrathecal chemotherapy.  Cancer. 1994;  73 3037-3040
    CrossrefPubMedGoogle Scholar
  • 56 Kleinschmidt-DeMasters B K, Yeh M. “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma.  Cancer. 1992;  70 2504-2507
    CrossrefPubMedGoogle Scholar
  • 57 Siegal T, Haim N. Cisplatin-induced peripheral neuropathy.  Cancer. 1990;  66 1117-1123
    CrossrefPubMedGoogle Scholar
  • 58 Cavaletti G, Marzorati L, Bogliun G et al.. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.  Cancer. 1992;  69 203-207
    CrossrefPubMedGoogle Scholar
  • 59 Gill J S, Windebank A J. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.  J Clin Invest. 1998;  101 2842-2850
    CrossrefPubMedGoogle Scholar
  • 60 Krarup-Hansen A, Rietz B, Krarup C et al.. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study.  Neuropathol Appl Neurobiol. 1999;  25 29-40
    PubMedGoogle Scholar
  • 61 Boogerd W, Huinink W W, Dalesio O, Hoppenbrouwers W J, van der Sande J. Cisplatin induced neuropathy: central, peripheral, and autonomic nerve involvement.  J Neurooncol. 1990;  9 255-263
    CrossrefPubMedGoogle Scholar
  • 62 Heinzlef O, Lotz J P, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy.  J Neurol Neurosurg Psychiatry. 1998;  64 667-669
    CrossrefPubMedGoogle Scholar
  • 63 Openshaw H, Slatkin N E, Stein A S, Hinton D R, Forman S J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia.  Cancer. 1996;  78 1899-1905
    CrossrefPubMedGoogle Scholar
  • 64 Imrie K R, Couture F, Turner C C, Sutcliffe S B, Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation.  Bone Marrow Transplant. 1994;  13 77-79
    PubMedGoogle Scholar
  • 65 Stein M E, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy.  Am J Clin Oncol. 1998;  21 248-249
    CrossrefPubMedGoogle Scholar
  • 66 Patel S R, Forman A D, Benjamin R S. High-dose ifosfamide-induced exacerbation of peripheral neuropathy.  J Natl Cancer Inst. 1994;  86 305-306
    CrossrefPubMedGoogle Scholar
  • 67 Koh S, Nelson M D, Kovanlikaya A, Chen L S. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.  Pediatr Neurol. 1999;  21 576-578
    CrossrefPubMedGoogle Scholar
  • 68 Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.  Semin Oncol. 2002;  29(Suppl 15) 21-33
    PubMedGoogle Scholar
  • 69 Wilson R H, Lehky T, Thomas R R et al.. Acute oxaliplatin-induced peripheral nerve hyperexcitability.  J Clin Oncol. 2002;  20 1767-1774
    CrossrefPubMedGoogle Scholar
  • 70 Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.  Cancer. 2002;  94 2434-2440
    CrossrefPubMedGoogle Scholar
  • 71 Chaudhry V, Eisenberger M A, Sinibaldi V J et al.. A prospective study of suramin-induced peripheral neuropathy.  Brain. 1996;  119 2039-2052
    CrossrefPubMedGoogle Scholar
  • 72 Soliven B, Dhand U K, Kobayashi K et al.. Evaluation of neuropathy in patients on suramin treatment.  Muscle Nerve. 1997;  20 83-91
    PubMedGoogle Scholar
  • 73 Cavaletti G, Bogliun G, Marzorati L et al.. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.  Cancer. 1995;  75 1141-1150
    CrossrefPubMedGoogle Scholar
  • 74 Forsyth P S, Balmaceda C, Peterson K et al.. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.  J Neurooncol. 1997;  35 47-53
    CrossrefPubMedGoogle Scholar
  • 75 Hilkens P H, Verweij J, Stoter G et al.. Peripheral neurotoxicity induced by docetaxel.  Neurology. 1996;  46 104-108
    PubMedGoogle Scholar
  • 76 New P Z, Jackson C E, Rinaldi D, Burris H, Barohn R J. Peripheral neuropathy secondary to docetaxel (Taxotere).  Neurology. 1996;  46 108-111
    PubMedGoogle Scholar
  • 77 van den Bent M J, Hilkens P H, Sillevis Smitt P A et al.. Lhermitte's sign following chemotherapy with docetaxel.  Neurology. 1998;  50 563-564
    PubMedGoogle Scholar
  • 78 Chaudhry V, Rowinsky E K, Sartorius S E, Donehower R C, Cornblath D R. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.  Ann Neurol. 1994;  35 304-311
    CrossrefPubMedGoogle Scholar
  • 79 Freilich R J, Balmaceda C, Seidman A D, Rubin M, DeAngelis L M. Motor neuropathy due to docetaxel and paclitaxel.  Neurology. 1996;  47 115-118
    CrossrefPubMedGoogle Scholar
  • 80 Chaudhry V, Chaudhry M, Crawford T O, Simmons-O'Brien E, Griffin J W. Toxic neuropathy in patients with pre-existing neuropathy.  Neurology. 2003;  60 337-340
    CrossrefPubMedGoogle Scholar
  • 81 Berger T, Malayeri R, Doppelbauer A et al.. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.  Eur J Cancer. 1997;  33 1393-1399
    CrossrefPubMedGoogle Scholar
  • 82 Molloy F M, Floeter M K, Syed N A et al.. Thalidomide neuropathy in patients treated for metastatic prostate cancer.  Muscle Nerve. 2001;  24 1050-1057
    CrossrefPubMedGoogle Scholar
  • 83 Chaudhry V, Cornblath D R, Corse A et al.. Thalidomide-induced neuropathy.  Neurology. 2002;  59 1872-1875
    CrossrefPubMedGoogle Scholar
  • 84 Casey E B, Jellife A M, Le Quesne P M, Millett Y L. Vincristine neuropathy: clinical and electrophysiological observations.  Brain. 1973;  96 69-86
    CrossrefPubMedGoogle Scholar
  • 85 Graf W D, Chance P F, Lensch M W et al.. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.  Cancer. 1996;  77 1356-1362
    CrossrefPubMedGoogle Scholar
  • 86 Weintraub M, Adde M A, Venzon D J et al.. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.  J Clin Oncol. 1996;  14 935-940
    PubMedGoogle Scholar
  • 87 Pace A, Bove L, Nistico C et al.. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.  J Neurol Neurosurg Psychiatry. 1996;  61 409-411
    CrossrefPubMedGoogle Scholar
  • 88 Apfel S C. Managing the neurotoxicity of paclitaxel and docetaxel with neurotrophic factors.  Cancer Invest. 2000;  18 564-573
    CrossrefPubMedGoogle Scholar
  • 89 Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.  Eur J Cancer. 2002;  38 1832-1837
    CrossrefPubMedGoogle Scholar
  • 90 Vahdat L, Papadopoulos K, Lange D et al.. Reduction of paclitaxel-induced peripheral neuropathy with glutamine.  Clin Cancer Res. 2001;  7 1192-1197
    PubMedGoogle Scholar
  • 91 Cascinu S, Catalano V, Cordella L et al.. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer.  J Clin Oncol. 2002;  20 3478-3483
    CrossrefPubMedGoogle Scholar

Edward J DropchoM.D. 

Department of Neurology, Indiana University School of Medicine

541 Clinical Drive, CL 291

Indianapolis, IN 46202